Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

GALT vs CNAT positioning in Nash Cirrhosis

As for CNAT positioning please see previous post 'GILD vs CNAT positioning in NASH Cirrhosis'

GALT GR MD 02 trial NASH CX trial is targeting compensated (or early decompensated) patients with high HPVG but excluding patients with CHILD PUGH score B or C or with MELD score above 15. So it is positioning itself as GILD Stellar 4 trial.

Child Pugh B and Child C target population, those at significant 1 year risk of death, will be only targeted by CNAT ENCORE PH and LF trials, where basically Emricasan has no current and potential future competition at the moment.